07:00 , Jun 15, 2015 |  BioCentury  |  Regulation

LDL in context

Discussion at last week's advisory committee meeting for the PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab suggest that, for first-in-class hypercholesterolemia candidates, the agency and the committee are leaning toward narrowing the use of LDL...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ia started

LipimetiX Development LLC began a double-blind, placebo-controlled, Australian Phase Ia trial to evaluate single and multiple ascending-doses of IV AEM-28 in about 36 healthy volunteers with elevated cholesterol. LipimetiX Development is a JV between Capstone...
07:00 , Sep 16, 2013 |  BioCentury  |  Finance

Benu's virtual play

Benu's virtual play New investment firm...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Capstone Therapeutics, LipimetiX deal

Capstone and LipimetiX formed a 60/40 JV, LipimetiX Development LLC, to develop LipimetiX's mimetics of apolipoprotein E (APOE) . LipimetiX has rights to the compounds from University of Alabama at Birmingham . Capstone will contribute...
07:00 , Jun 7, 2010 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E , a protein that can target two additional hepatic receptors capable of...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Benu Biopharma Inc., Exponential Pharma Ventures LLC deal

Benu Biopharma and Exponential Pharma Ventures formed a new virtual company called LipimetiX LLC to develop apolipoprotein E (APOE) mimetics. The newco's lead compounds, AEM-18 and AEM-28 , are in preclinical development to treat refractory...